An Open Label Multi-part First-in-human Study of Oral LMI070 in Infants With Type 1 Spinal Muscular Atrophy
Phase of Trial: Phase I/II
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Branaplam (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Novartis; Novartis Pharmaceuticals
- 26 Oct 2017 Planned End Date changed from 1 Aug 2017 to 14 Nov 2019.
- 26 Oct 2017 Status changed from active, no longer recruiting to recruiting.
- 23 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 14 Nov 2019.